Home › Compare › OPTZF vs ABBV
OPTZF yields 42.33% · ABBV yields 3.06%● Live data
📍 OPTZF pulled ahead of the other in Year 1
Combined, OPTZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OPTZF + ABBV for your $10,000?
OptiCept Technologies AB (publ) develops a technology that controls and applies electrical pulses to optimize various biological processes in Sweden and internationally. The company offers foodtech products, such as juiceCEPT, a c machine; juiceCEPT+, an application for the juice industry; oliveCEPT that deploys a pre-treatment to olive paste in extra virgin olive oil production (EVOO) for better quality of the product and increases extracted EVOO yield; wineCEPT, a technology for the treatment of targets cell membranes in biomass; and dryCEPT to reduce drying time, enhanced flavor, and vivid color on the final dried products. It also provides planttech products, including OptiBoost for cut flowers and OptiBoost for cuttings. The company's products are used for applications in beer, dairy, flowers, food oils, juice, plant milk, and wine. The company was formerly known as OptiFreeze AB (publ) and changed its name to OptiCept Technologies AB (publ) in July 2021. OptiCept Technologies AB (publ) was incorporated in 2011 and is headquartered in Lund, Sweden.
Full OPTZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.